Evidence first
Traceable sources, critical evaluation and clear separation of facts from assumptions.
RESEARCH WITH A HUMAN POINT OF VIEW
Make sense
of complexity.
Find your next move.
I turn complex pharmaceutical and healthcare markets into clear evidence, practical forecasts and decisions teams can act on.
✳Life sciences research & consulting
10 years focused on research, forecasting & consulting
10 years focused on research, forecasting & consulting
EVIDENCE
→ INSIGHT
→ INSIGHT
THE BIG PICTUREData is a starting point.
Clarity is the outcome.↗
Clarity is the outcome.↗
CURIOUS
BY DESIGN ✳
01 / 04
BY DESIGN ✳
MARKET INTELLIGENCECOMMERCIAL FORECASTINGSTRATEGIC CLARITYSCROLL TO EXPLORE ↓
Market sizing✳Commercial forecasting✳Competitive intelligence✳Pipeline assessment✳AI-enabled market intelligence✳Forecasting analytics✳Evidence synthesis✳
01 — HOW I THINK
Good research doesn’t just answer questions.
It changes the questions worth asking.
Healthcare markets are full of moving parts: science, access, competition, policy and commercial reality. My role is to bring those signals together without losing the nuance.
Expect a structured approach, transparent assumptions and outputs built for real decisions—not just a polished deck.
See how I can help ↘Commercial context
Connect clinical, competitive and market signals to business implications.
Useful by design
Models, matrices and narratives that stakeholders can understand and use.
02 — WHAT I DO
Research, shaped
around your challenge.
Flexible support for consulting teams, pharmaceutical companies, biotech innovators and research organisations—from a focused sprint to a full market assessment.
Market research & sizing
Market landscapes, segmentation, demand drivers, patient and treatment context, top-down/bottom-up triangulation.
Commercial forecasting
Patient-based and market-based forecasts, launch scenarios, assumptions, sensitivity analysis and opportunity models.
Competitive intelligence
Competitor profiles, pipeline tracking, clinical milestones, regulatory signals, benchmarking and strategic implications.
Therapeutic & technology assessment
Evidence-led assessments across oncology, biosimilars, vaccines, genomics, women’s health and medical devices.
Decision-ready deliverables
Excel models, competitor matrices, research reports, PowerPoint narratives and Power BI-ready analysis.
03 — AI & ANALYTICS
Life sciences intelligence,
enhanced by AI.
Combining pharmaceutical domain knowledge, evidence-led research and AI-assisted workflows to turn complex information into clearer commercial decisions.
✳
AI can accelerate information discovery and structuring. Strong research still depends on source quality, analytical judgement, transparent assumptions and human validation.
AI-assisted market intelligence
Structure and synthesise information from clinical trials, regulatory updates, company disclosures, scientific publications and pipeline announcements.
MARKET & COMPETITOR SIGNALSForecasting & scenario analytics
Combine patient-based forecasting, market drivers, scenario analysis and sensitivity testing to make assumptions and forecast risks more visible.
ASSUMPTIONS · SCENARIOS · RISKSGenerative AI & evidence synthesis
Explore LLM- and RAG-supported workflows for literature review, document extraction, structured evidence summaries and research organisation.
TRACEABLE EVIDENCE SYNTHESISClinical pipeline intelligence
Organise trial and pipeline information to assess development milestones, competitor activity, therapeutic landscapes and potential launch implications.
PIPELINE & LANDSCAPE MONITORINGAI in drug development & digital health
Assess AI-enabled discovery, clinical development, precision medicine and digital health markets, including adoption drivers and commercial opportunities.
TECHNOLOGY & MARKET ASSESSMENTDecision analytics & visualisation
Translate structured research and analytical models into Excel outputs, Power BI dashboards, competitor matrices and decision-ready presentations.
INSIGHTS · DASHBOARDS · DECISIONSOur principleAI-assisted research. Expert interpretation. Evidence-based recommendations.
04 — SELECTED WORK
Complex topics.
Clearer perspectives.
Representative project themes and sample work formats. These are illustrative areas of expertise, not claims of confidential client deliverables.
THERAPEUTIC
LANDSCAPE
LANDSCAPE
+
01 / ONCOLOGYOncology & emerging therapies
Map treatment landscapes, clinical development, launch timing and potential commercial implications.
DATA → DECISIONS02 / DIGITAL LIFE SCIENCES
Genomics & research technologies
Assess market structure, adoption drivers, use cases and the evolving technology ecosystem.
BIO
LOGICS03 / BIOSIMILARS
LOGICS03 / BIOSIMILARS
Biosimilars & biologics
Compare portfolios, regulatory milestones, access factors and competitive positioning.
SCENARIO
PLANNING04 / FORECASTING
Forecasts built on assumptions
Structure the drivers, make assumptions visible and test what changes the outlook.
ILLUSTRATIVE CASE STUDIES · 2026 MARKET THEMES
These independent research demonstrations show how I structure a commercial question, build an evidence base and translate analysis into decision-ready outputs. They are illustrative examples, not commissioned client engagements or claims of completed client work.
01 / METABOLIC HEALTHMARKET FORECASTING
Next-generation obesity therapeutics: market opportunity & forecast framework
Business question How could evolving oral GLP-1s, combination regimens and differentiated mechanisms reshape the obesity treatment landscape through 2030?
Analytical approach
- Define treated and addressable patient populations by geography.
- Segment injectable, oral and combination treatment options.
- Assess clinical differentiation, launch timing, access and persistence.
- Build patient-based revenue scenarios with pricing and share sensitivities.
Illustrative outputs
- Patient funnel and treatment flow model.
- Competitor and pipeline tracker.
- Base, upside and downside forecast scenarios.
- Key adoption barriers and commercial watchpoints.
Decision valueIdentify the assumptions that matter most to market expansion, product differentiation and forecast uncertainty.
02 / ONCOLOGYCOMPETITIVE INTELLIGENCE
Antibody-drug conjugates: competitive landscape & pipeline intelligence
Business question Where are ADC assets concentrating, how differentiated are emerging programs and what could influence future competitive positioning?
Analytical approach
- Map assets by target, payload, linker, tumour type and developer.
- Track trial phase, design, endpoints, readouts and regulatory milestones.
- Compare clinical profiles and relevant standard-of-care context.
- Review partnerships, licensing activity and competitive whitespace.
Illustrative outputs
- Asset-level pipeline database.
- Target and tumour-type heat map.
- Competitor benchmarking matrix.
- Milestone watchlist and strategic implications.
Decision valueClarify where competition is intensifying, which assets warrant monitoring and where differentiation may matter.
03 / ADVANCED THERAPIESCOMMERCIAL ASSESSMENT
Cell & gene therapies: translating pipeline momentum into commercial readiness
Business question What determines whether promising advanced therapies can move from clinical progress to scalable patient access and sustainable adoption?
Analytical approach
- Segment approved and investigational therapies by modality and indication.
- Assess clinical maturity, regulatory pathways and geographic reach.
- Evaluate manufacturing capacity, treatment-centre readiness and delivery complexity.
- Examine affordability, reimbursement, referral pathways and patient access.
Illustrative outputs
- Modality and indication landscape.
- Regulatory and clinical milestone tracker.
- Commercial readiness scorecard with transparent criteria.
- Market access risks and opportunity map.
Decision valueConnect pipeline activity with the operational, access and economic factors that shape real-world commercialisation.
Context for topic selection2026 industry publications identify obesity medicines, ADCs and cell/gene therapies as important areas of innovation and commercial focus. The case studies above are proposed analytical frameworks, not reproduced market forecasts.Deloitte 2026 Life Sciences Outlook ↗ISCT Global Regulatory Report 2026 ↗WTW: Anti-obesity medicines outlook ↗
05 — PROFESSIONAL RECOMMENDATIONS
Good work is built
with good people.
A few words from professionals who have worked alongside me across life sciences research and consulting.
“
Shrikant consistently took ownership of his work and met deadlines, and with a positive attitude and collaborative work made it easy to work with him, always open to taking feedback.
Kalyani Ksr bAssistant Manager · BCC Research · Former ManagerLinkedIn recommendation · July 27, 2026
LinkedIn profile ↗“
Shrikant is someone you can always rely on. His attitude towards doing things right is something to learn from. Excellent clarity on concepts, always trying to ask the right questions and consolidating everything to provide clients with the best possible outcomes.
Rupesh JasudFormer Colleague · MarketsandMarkets
LinkedIn profile ↗Recommendations originally shared on LinkedIn. Names and profile links are provided for professional attribution.
06 — THE PROCESS
From a messy question
to a clear next step.
Every engagement is tailored, but the work follows a simple discipline: align on the decision, build the evidence, test the logic and communicate what matters.
Talk through your brief ↗01
Frame the question
Agree scope, audience, decision need and deliverables.
02
Gather & triangulate
Review credible sources, compare signals and document gaps.
03
Model & challenge
Test assumptions, explore scenarios and check consistency.
04
Make it actionable
Translate findings into clear implications and next steps.
A NOTE ON MY APPROACH
PUNE, INDIA · WORKING GLOBALLYCuriosity
with a
commercial lens.
07 — A LITTLE ABOUT ME
Science-minded.
Business-focused.
I’m Shrikant Bolli, a life sciences market research and consulting professional with 15 years of overall experience, including around 10 years focused on research, forecasting and consulting, alongside earlier pharmaceutical commercial experience with Johnson & Johnson and Novartis.
With an academic foundation in Pharmacy (B.Pharm) and an MBA in Marketing, I bring together scientific understanding, pharmaceutical industry exposure and commercial thinking. I’ve worked across research and consulting environments and understand how evidence becomes market perspective, competitive context and commercial decisions.
15Years overall
experience
experience
10+Years in research
& consulting
& consulting
75+Research reports
completed
completed
25+Consulting projects
delivered
delivered
08 — YOUR NEXT PROJECT
Let’s make the
complex clearer.
Have a research question, a forecasting challenge or a project that needs an extra pair of experienced hands? Tell me what you’re working on.
✳Freelance assignments · Consulting support
Research partnerships · Relevant full-time roles
Research partnerships · Relevant full-time roles
START A CONVERSATION↗
Emailshrikant.bolli@gmail.com↗Phone+91 99708 23213↗LinkedInhttps://www.linkedin.com/in/shrikant-bolli/↗Send a project brief ↗Please avoid sending confidential patient information or proprietary data in an initial enquiry.